Hypoallergenic molecules for subcutaneous immunotherapy

Expert Review of Clinical Immunology

Volumn 12, Issue 1, 2016, Pages 5-7

  Jongejan, Laurian ^a   Van Ree, Ronald ^a   Poulsen, Lars K ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

allergy; FAST; fish; hypoallergen; immunotherapy; parvalbumin; peach

Indexed keywords

ALLERGEN; CYSTEINE DERIVATIVE; EPITOPE; GLUTARALDEHYDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; INSECT VENOM; INTERLEUKIN 10; LIPID TRANSFER PROTEIN; PARVALBUMIN; PEANUT EXTRACT; POLLEN ANTIGEN; RECOMBINANT PROTEIN; SERINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; FISH PROTEIN; VENOM;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGENICITY; ALLERGY; ANTIBODY PRODUCTION; B LYMPHOCYTE; BINDING SITE; CALCIUM BINDING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FISH ALLERGY; FOOD ALLERGY; GOOD MANUFACTURING PRACTICE; HUMAN; HYPOALLERGENICITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INSECT ALLERGY; NONHUMAN; PEACH ALLERGY; PEANUT ALLERGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PROTEIN INDUCTION; PROTEIN SECRETION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; T LYMPHOCYTE; TH2 CELL; TOXICITY TESTING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; DESENSITIZATION; FOOD; HYPERSENSITIVITY; IMMUNOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; FISH PROTEINS; FOOD; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; VENOMS;

EID: 84949112096     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2016.1103182     Document Type: Review

References (25)

1. Bjorksten B, Clayton T, Ellwood P, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19(2):110-124.
2. Zhang Y, Zhang L. Prevalence of allergic rhinitis in china. Allergy Asthma Immunol Res. 2014;6(2):105-113.
3. Kudzyte J, Griska E, Bojarskas J. Time trends in the prevalence of asthma and allergy among 6-7-year-old children. Results from ISAAC phase I and III studies in Kaunas, Lithuania. Medicina (Kaunas, Lithuania). 2008;44(12):944-952.
4. Liao MF, Liao MN, Lin SN, et al. Prevalence of allergic diseases of schoolchildren in central taiwan. From ISAAC surveys 5 years apart. J Asthma Off J Assoc Care Asthma. 2009;46(6):541-545.
5. Nwaru BI, Hickstein L, Panesar SS, et al. Prevalence of common food allergies in Europe: a systematic review and metaanalysis. Allergy. 2014;69(8):992-1007.
6. Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007;120 (3):638-646.
7. Zuidmeer L, Goldhahn K, Rona RJ, et al. The prevalence of plant food allergies: a systematic review. J Allergy Clin Immunol. 2008;121(5):1210-1218.
8. Sicherer SH, Munoz-Furlong A, Godbold JH, et al. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol. 2010;125(6):122-126.
9. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621-631.
10. van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131(4):1204-1212.
11. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172(5):3252-3259.
12. Plewako H, Wosinska K, Arvidsson M, et al. Production of interleukin-12 by monocytes and interferon-gamma by natural killer cells in allergic patients during rush immunotherapy. Ann Allergy Asthma Immunol. 2006;97 (4):464-468.
13. Senti G, Johansen P, Martinez GJ, et al. Efficacy and safety of allergen-specific immunotherapy in rhinitis, rhinoconjunctivitis, and bee/wasp venom allergies. Int Rev Immunol. 2005;24(5-6):519-531.
14. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288-1296.
15. Pauli G, Malling HJ. The current state of recombinant allergens for immunotherapy. Curr Opin Allergy Clin Immunol. 2010;10(6):575-581.
16. Jutel M, Solarewicz-Madejek K, Smolinska S. Recombinant allergens: the present and the future. Hum Vaccin Immunother. 2012;8(10):1534-1543.
17. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122(5):951-960.
18. Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99(6 Pt 1):744-751.
19. Oppenheimer JJ, Nelson HS, Bock SA, et al. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90(2):256-262.
20. Zuidmeer-Jongejan L, Fernandez-Rivas M, Poulsen LK, et al. FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies. ClinTransl Allergy. 2012;2 (1):5.
21. Vrtala S, Fohr M, Campana R, et al. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine. 2011;29 (11):2140-2148.
22. Toda M, Reese G, Gadermaier G, et al. Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. J Allergy Clin Immunol. 2011;128(5):1022-1030.
23. Bugajska-Schretter A, Elfman L, Fuchs T, et al. Parvalbumin, a cross-reactive fish allergen, contains IgE-binding epitopes sensitive to periodate treatment and Ca2+ depletion. J Allergy Clin Immunol. 1998;101(1 Pt 1):67-74.
24. Swoboda I, Bugajska-Schretter A, Linhart B, et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol. 2007;178(10):6290-6296.
25. Zuidmeer-Jongejan L, Huber H, Swoboda I, et al. Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy. Int Arch Allergy Immunol. 2015;166(1):41-51.